John G Ullman & Associates Inc. Has $23,420,000 Stake in Johnson & Johnson (JNJ)
John G Ullman & Associates Inc. cut its position in Johnson & Johnson (NYSE:JNJ) by 22.6% during the third quarter, according to its most recent filing with the SEC. The fund owned 198,257 shares of the company’s stock after selling 58,052 shares during the period. Johnson & Johnson comprises 4.8% of John G Ullman & Associates Inc.’s portfolio, making the stock its largest position. John G Ullman & Associates Inc.’s holdings in Johnson & Johnson were worth $23,420,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Bank of Montreal Can acquired a new stake in shares of Johnson & Johnson during the second quarter worth about $858,505,000. Emerald Acquisition Ltd. acquired a new stake in shares of Johnson & Johnson during the second quarter worth about $805,455,000. Vanguard Group Inc. boosted its stake in shares of Johnson & Johnson by 2.2% in the second quarter. Vanguard Group Inc. now owns 184,512,652 shares of the company’s stock worth $22,381,384,000 after buying an additional 3,924,090 shares during the last quarter. BlackRock Fund Advisors boosted its stake in shares of Johnson & Johnson by 5.5% in the second quarter. BlackRock Fund Advisors now owns 42,089,045 shares of the company’s stock worth $5,105,401,000 after buying an additional 2,192,319 shares during the last quarter. Finally, Capital World Investors boosted its stake in shares of Johnson & Johnson by 10.3% in the second quarter. Capital World Investors now owns 22,025,323 shares of the company’s stock worth $2,671,672,000 after buying an additional 2,050,323 shares during the last quarter. 64.13% of the stock is currently owned by institutional investors.
Johnson & Johnson (NYSE:JNJ) traded down 0.83% during trading on Monday, reaching $113.18. 4,439,608 shares of the company were exchanged. Johnson & Johnson has a 1-year low of $94.28 and a 1-year high of $126.07. The stock has a market capitalization of $307.91 billion, a P/E ratio of 19.87 and a beta of 0.75. The company’s 50-day moving average price is $116.14 and its 200-day moving average price is $118.35.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.66 by $0.02. Johnson & Johnson had a net margin of 22.03% and a return on equity of 25.30%. The business had revenue of $17.80 billion for the quarter, compared to analyst estimates of $17.71 billion. During the same quarter in the prior year, the business posted $1.49 EPS. Johnson & Johnson’s revenue for the quarter was up 4.2% compared to the same quarter last year. On average, equities analysts forecast that Johnson & Johnson will post $6.72 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be paid a dividend of $0.80 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.29. The ex-dividend date of this dividend is Friday, November 18th. This represents a $3.20 dividend on an annualized basis and a yield of 2.80%. Johnson & Johnson’s dividend payout ratio is presently 56.64%.
A number of brokerages have issued reports on JNJ. Argus reissued a “buy” rating and set a $145.00 target price on shares of Johnson & Johnson in a report on Friday, October 21st. Vetr cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $119.60 target price on the stock. in a report on Tuesday, November 1st. Leerink Swann reissued a “buy” rating on shares of Johnson & Johnson in a report on Sunday, September 11th. Jefferies Group boosted their target price on shares of Johnson & Johnson from $113.00 to $119.00 and gave the company a “hold” rating in a report on Thursday, August 4th. Finally, Societe Generale reaffirmed a “hold” rating and issued a $116.00 price target on shares of Johnson & Johnson in a report on Sunday, October 23rd. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus price target of $121.02.
In related news, Director Charles Prince purchased 875 shares of the business’s stock in a transaction on Friday, October 21st. The shares were acquired at an average price of $114.11 per share, for a total transaction of $99,846.25. Following the purchase, the director now owns 26,520 shares of the company’s stock, valued at approximately $3,026,197.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.11% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.